Overview of Direct Order Process for COVID-19 Therapeutics
Year Developed: 2021
Resource Type: Document.Primary Audience: Administrative Staff; C-Suite (CEO-CFO, CIO, COO, etc.); Clinicians
Language(s): English
Sponsored by: NACHC
Developed by: Assistant Secretary for Preparedness and Response (See other resources developed by this organization).
Resource Summary: The United States Government (USG) is responsible for the allocation and distribution of monoclonal antibody (mAb) therapeutics for the treatment of COVID-19 as per the Emergency Use Authorizations (EUA) issued by the U.S. Food and Drug Administration (FDA). The USG has developed a process for sites to directly order from the distributor, AmerisourceBergen (ABC).
Resource Topic: Clinical Issues
Resource Subtopic: —Clinical Issues, COVID-19.
This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,625,000 with 0 percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov.